In the first half of 2026, the Russian pharmaceutical industry demonstrated confident positive dynamics in both value and physical terms. The total production volume of finished medicinal products (FMPs) by domestic and localized pharmaceutical enterprises during this period reached RUB 558.8 billion (at manufacturer selling prices, including VAT), reflecting a 17.9% increase compared to the same period in 2025. According to the database "Production of Medicinal Products in Russia" from the analytical company RNC Pharma, positive results were also recorded in physical indicators: approximately 1.99 billion consumer packages were released into civil circulation, corresponding to 42.9 billion minimum dosage units (MDU). Compared to Q1–Q2 2025, production growth was 6.4% in packages and 7.2% in MDU terms.

June 2026 saw an acceleration in the growth rate of Russian pharmaceutical production, with monetary growth outpacing physical indicators. FMP shipments for the month exceeded RUB 95.2 billion, 22.1% higher than in June 2025. In physical terms, pharmaceutical enterprises released 349.4 million consumer packages, or more than 7.5 billion MDU, into civil circulation. Compared to the same month last year, growth was 14.1% in packages and 15.5% in MDU, which significantly influenced the overall results for the first half of the year.

The key driver of growth in the drug production structure in the first half of 2026 was the hypoglycemic drug segment (EphMRA group A10), whose production volume increased by more than 41% in packages. The leading position in this category is held by the original brand Forxiga (INN dapagliflozin) from AstraZeneca, which showed annual production growth of 55%. Notably, the brand demonstrates high growth despite the start of generic dapagliflozin sales in Russian pharmaceutical retail. At the same time, the domestic brand Tirzetta (INN tirzepatide) from Promomed demonstrated tremendous growth dynamics in the diabetes drug segment, with production volumes increasing 9-fold compared to the first half of 2025.

High growth rates during the reporting period were also demonstrated by the gastrointestinal drug segment (group A03), with shipment volumes increasing by 38% year-on-year. The main contribution here came from unbranded Drotaverine (key manufacturer Velfarm), as well as the brands Duspatalin from Abbott and Trimedat from Valenta.

In contrast to the growing segments, the topical antirheumatic drug category (group M02) recorded negative dynamics during the reporting period: shipment volumes in consumer packages decreased by 30%. In particular, production of the leading unbranded drug Diclofenac decreased by 11%. During the reporting period, about 15 domestic suppliers of this drug were recorded, the main one being Binnopharm Group. At the same time, the 72% decline in production of Ant Alcohol is of a technical correction nature: it is due to the high base of the previous year, when abnormally high production volumes were recorded, while in the current period, indicators are returning to levels traditional for this product.

In the structure of total shipments by physical volume, analgesics (group N02) hold the lead with a 6.4% package share. Second place is occupied by drugs affecting the renin-angiotensin system (group C09), accounting for 5.5%. In third place rose anti-inflammatory and antirheumatic drugs (group M01) with a 4.4% share, displacing systemic antibacterial drugs (group J01), which held a 4.6% market share in the first half of last year. Notably, among these leading groups, negative production dynamics were recorded only in the renin-angiotensin system drugs segment, with the decline affecting exclusively consumer packages (-4%), while an increase of 2% was noted in minimum dosage units.

Fig. Production Volume of Finished Medicinal Products in Russia (including the output of foreign pharmaceutical companies at their own and contract sites) in 2022–2025 and Q1–Q2 2026, in physical (packages) and monetary terms (RUB, including VAT)